AbCellera Biologics Inc. (ABCL) /
The cash flow of AbCellera Biologics Inc. over the past 7 years
Chart AbCellera Biologics Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2019–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, AbCellera Biologics Inc.'s operating cash flow was -$131.29M and its capital expenditures $42.77M, leaving free cash flow of -$174.07M. Free cash flow was above zero in 3 of the 7 years shown. It ranged from -$186.95M in fiscal 2024 to $206.7M in fiscal 2022. Capital expenditures were highest in fiscal 2024, at $78.4M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$131.29M | $42.77M | -$174.07M |
| 2024ended Dec 31, 2024 | -$108.56M | $78.4M | -$186.95M |
| 2023ended Dec 31, 2023 | -$43.88M | $76.95M | -$120.82M |
| 2022ended Dec 31, 2022 | $277.36M | $70.66M | $206.7M |
| 2021ended Dec 31, 2021 | $244.58M | $58.45M | $186.13M |
| 2020ended Dec 31, 2020 | $22.69M | $9.67M | $13.02M |
| 2019ended Dec 31, 2019 | $2.69M | $4M | -$1.3M |
Fiscal years as AbCellera Biologics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on AbCellera Biologics Inc.
- The revenue of AbCellera Biologics Inc.
- The profitability of AbCellera Biologics Inc.
- The debt of AbCellera Biologics Inc.
- All of AbCellera Biologics Inc.'s financials, charted
Companies of a similar size
- GEOThe GEO Group, Inc.
- RUSHARUSH ENTERPRISES, INC.
- EQPTEquipmentShare.com Inc
- SLMSLM Corp
- ACMRACM Research, Inc.
Not investment advice. This page shows what AbCellera Biologics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.